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Abstract
Background: Gene transcription patterns associated with activation of oncogenes Myc, c-Src, beta-catenin, E2F3, H-Ras,
HER2, EGFR, MEK, Raf, MAPK, Akt, and cyclin D1, as well as of the cell cycle and of androgen signaling have been generated
in previous studies using experimental models. It was not clear whether genes in these ‘‘oncogenic signatures’’ would show
coordinate expression patterns in human prostate tumors, particularly as most of the signatures were derived from cell
types other than prostate.
Principal Findings: The above oncogenic pathway signatures were examined in four different gene expression profile
datasets of human prostate tumors (representing ,250 patients in all), using both Q1-Q2 and one-sided Fisher’s exact
enrichment analysis methods. A significant fraction (,5%) of genes up-regulated experimentally by Myc, c-Src, HER2, Akt, or
androgen were co-expressed in human tumors with the oncogene or biomarker corresponding to the pathway signature.
Genes down-regulated experimentally, however, did not show anticipated patterns of anti-enrichment in the human
tumors.
Conclusions: Significant subsets of the genes in these experimentally-derived oncogenic signatures are relevant to the
study of human prostate cancer. Both molecular biologists and clinical researchers could focus attention on the relatively
small number of genes identified here as having coordinate patterns that arise from both the experimental system and the
human disease system.
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Introduction
Cancer is a disease characterized by DNA damage and
widespread deregulation of cell signaling and gene transcription.
Genes with roles in cancer can be broadly grouped into
oncogenes, tumor supressors, and DNA damage-associated genes.
Oncogenes promote cancer by over-expression or hyper-activa-
tion. The molecular pathways leading to oncogenesis and tumor
progression are diverse [1]. Much progress has been made in the
past 30 years in defining these pathways at the level of signal
transduction involving protein-to-protein interaction. However,
signal transduction leads through the chain of events to
transcriptional regulation of a specific set of genes [1]. With the
advent of global gene expression profiling technology within the
last ten years, we can now more readily examine oncogenic
pathways at the level of gene transcription. Through the use of
experimental models such as cell cultures or transgenic mice, one
may turn up the expression or activity of a specific gene and
observe which genes are regulated as a result.
Here an oncogenic pathway signature will be defined to mean a
set of genes that show a specific pattern of up- or down-regulation
when a given pathway associated with oncogenesis is activated.
Oncogenic signatures observed experimentally have potential use
for inferring pathway deregulation in human tumors. In a seminal
study by Lamb et al. [2], a set of genes induced by cyclin D1 in an
in vitro model were found to be co-expressed as a group with cyclin
D1 mRNA in multiple expression profile datasets of human
tumors of various types. In a recent study by Bild et al. [3], gene
signatures of Myc, Ras, E2F3, Src, and beta-catenin defined in vitro
were used to predict Ras mutation status in human lung tumors
and to predict the response of a panel of breast cancer cell lines to
Src or Ras inhibitors. In another study by Creighton et al. [4], a
signature of the MAP kinase pathway was defined from gene
expression profiles of ErbB-2 (HER2), EGFR, Raf, and MEK in
MCF-7 cells; this MAPK signature was found to share extensive
similarities with signatures of ER-negative human breast cancer,
which commonly has hyper-activated MAPK.
The oncogenic pathway signatures described above were
generated from gene expression profiling of breast cell cultures.
One question addressed here was which signatures could be
considered relevant to human cancers of a different cell type from
breast, in other words, whether genes associated with a given
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1816pathway in an experimental model show patterns of expression in
human tumors that would be consistent with that pathway
association. In the case of the Lamb cyclin D1 signature, human
tumors of various cell types (including breast and prostate) that had
high levels of cyclin D1 were found to express high levels of genes
in the cyclin D1 signature [2]. This present study explored
whether oncogenic signatures from other studies followed similar
patterns in human prostate cancer. The focus of this study was in
prostate cancer, as it is the most commonly occurring cancer in
males in the United States, and as there were several profile
datasets of human prostate cancer that were publically available.
Here, mRNA signatures of oncogenes Myc, c-Src, beta-catenin,
E2F3, H-Ras, HER2, EGFR, MEK, Raf, MAPK, Akt, and cyclin
D1, along with signatures of the cell cycle and of androgen
signaling, were collected from eight previously published studies.
As there have been multiple profiling studies of human prostate
tumors [5–8], one can look for gene expression patterns that are
common across independent datasets [9]. These oncogenic
signatures were therefore examined in four different profile
datasets of prostate tumors. As mentioned above, the aim of this
study was to determine if these experimentally-defined oncogenic
pathway signatures were relevant to human prostate cancer. The
specific hypothesis tested was that human prostate tumors with
(relatively) high mRNA levels of a given oncogene should also
show high levels of the group of genes found over-expressed in the
experimental setting when the same oncogene is turned up. One
important outcome of this analysis was a catalog of the genes from
a given experimentally-derived pathway signature that also had
expression patterns considered relevant to the human tumors,
which provides a resource for future functional studies.
Results
A collection of gene transcription signatures of
oncogenic pathways from various studies
Using gene expression profile datasets of cell culture and mouse
models from previously published studies (listed in Table 1), gene
signatures of 14 different oncogenic pathways were defined. These
signatures are described in Table 2 and shown graphically in
Figure 1. The pathways represented by these signatures were the
following: (1) Myc, c-Src, beta-catenin, E2F3, and H-Ras, from the
study by Bild et al. [3]; (2) erbB-2 (HER2), EGFR, MEK, Raf, and
MAPK from Creighton et al. [4]; (3) the cell cycle from Whitfield et
al. [10]; (4) androgen receptor (AR) signaling, from Deprimo et al.
[11]; (5) AR signaling, from Chen et al. [12]; (6) Myc, from Coller
et al. [13]; (7) cyclin D1, from Lamb et al. [2]; and (7) Akt, from
Majumder et al. [14]. The unique named genes involved in each of
these signatures are listed in Supplementary Data File S1.
For each oncogenic signature, one set of genes were up-
regulated and another set were down-regulated in response to
activation of the associated pathway. Statistical criteria for defining
each signature are given in the Methods section. Where selecting
genes from profile data is a balance between false negatives and
false positives, the selection cutoffs is this study leaned towards
having fewer false negatives and more gene information. The p-
value cutoffs used to define each signature were, in a sense,
arbitrarily chosen, the idea being that a ‘‘sizable’’ number of genes
(on the order of a few to several hundred) were desired to represent
each pathway. Because of the wide spectrum of experimental
systems, conditions, laboratories, and array platforms represented
among all of the profile datasets, it was not possible to analyze all
of the datasets in the same way and to use a single p-value cut off
(e.g. p,0.01 for each comparison). There are many possible
alternative methods and thresholds for defining the oncogenic
signatures that might have been used and which could have been
considered equally valid. The author believes that any reasonable
analytic approach for defining signatures that yielded numbers of
genes comparable to those in Table 2 would have resulted in the
same overall patterns of enrichment being observed between the
signatures and the human tumors.
Different oncogenic pathways may regulate common genes.
The oncogenic signatures in this study were compared with each
other to see which pairs of signatures shared significant gene
overlap. These signature-to-signature associations are shown
graphically in Figure 1I (focusing only on the set of genes up-
regulated in each signature). A significant overlap of 40 genes
between the set up-regulated by Myc in the Bild dataset (993
unique named genes) and the set up-regulated in the Coller dataset
(252 genes) was observed (expected 18 genes, one-sided Fisher’s
exact p,1E-06, using as the reference population the entire set of
14130 genes represented among any of the array platforms), which
shows good agreement between signatures of the same pathway
generated independently by different labs using different experi-
mental systems. Similarly, significant overlap was observed
between the Deprimo and Chen sets of androgen-inducible genes
(87 genes overlapping between 259 and 559 genes, respectively,
one-sided Fisher’s exact p,1E-57).
Furthermore, significant overlap was observed between signa-
tures representing different pathways. The overlap between the
Creighton erbB-2, EGFR, Raf, and MEK signatures had been
noted previously [4], and was defined as a common MAPK
signature. The overlap between the Bild Ras signature and the
Creighton MAPK-associated signatures makes sense, as Ras is also
a key intermediate of the MAPK pathway. In addition, the
signature genes for cell cycle regulator E2F3 in the Bild data
overlapped significantly with the set of genes correlated with cell
cycle progression in the Whitfield data. Other signature-to-
signature associations appear novel and intriguing, such as an
association between the Akt pathway and the MAPK-associated
pathways (Figure 1I). It is important to note that different
signatures may share common genes, yet show widespread
differences at the same time. For example, the Creighton
MAPK-associated signatures shared a common MAPK signature,
yet each of these signatures also had a distinct expression pattern
from the other signatures (Figure 1B). The complete lists of
corresponding genes overlapping among the various signatures are
provided as Supplementary Data File S2.
Genes up-regulated experimentally by Myc, c-Src, HER2,
Akt, or androgen are co-expressed in human prostate
tumors with Myc, c-Src, HER2, Akt, or PSA, respectively
The oncogenic pathway signatures of Table 2 and Figure 1 were
derived from a number of experimental models, several of these
signatures being derived from breast cell cultures in particular. An
important question was whether these signatures would be
relevant to the study of human prostate cancer, or would simply
represent tissue-specific or model-specific effects on gene expres-
sion. Previously, cyclin D1-regulated genes from the Lamb profile
dataset and Myc-regulated genes from the Coller dataset were
each shown to be coordinately expressed with CCND1 and MYC
mRNA expression, respectively, in various tumor datasets [2,15].
Here, the entire collection of oncogenic signatures from Table 2
was examined in each of four different expression profile datasets
of primary human prostate cancers (PCA) from previous studies
[5–8] (listed in Table 1), representing 253 individual prostate cases
in all (Glinsky et al. dataset: 79 tumors, Yu: 60, Lapointe: 62,
Singh: 52). Seven individual genes represented in the human
datasets were of particular interest: KLK3 (which encodes prostate-
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ERBB2, EGFR, CCND1, and AKT1. Each of these genes is an
oncogene commonly over-expressed in cancers, with the exception
of KLK3, a well-known gene target of androgen signaling. The
hypothesis tested below with each of these seven genes was that
prostate tumors with high expression (relative to other tumors) of
either an oncogene or a biomarker of an oncogenic pathway
would also show high expression of a significant number of genes
up-regulated experimentally in the corresponding pathway
signature. Additionally, these tumors with relatively high oncogene
levels might show under-expression of a significant number of
genes down-regulated in the pathway signature.
For each of the seven oncogenes mentioned above, the genes
most correlated (i.e. similar) in expression to the given oncogene
Table 1. Public gene expression profile datasets used in this study.
Study data source array platform # probes
# unique
(human) genes
Oncogenic signature datasets
Whitfield, et al. [10] SMD spotted cDNA 43896 14130
Deprimo, et al. [11] SMD spotted cDNA 33721 12934
Chen, et al. [12] GEO (GSE846) Affymetrix U133A 22283 12768
Coller, et al. [13] Broad Institute Affymetrix HUM6000-1,2,3,4 7252 3139
Bild, et al. [3] GEO (GSE3151) Affymetrix U133 Plus 2 54675 18134
Creighton, et al. [4] GEO (GSE3542) Affymetrix U133A 22283 12768
Lamb, et al. [2] Broad Institute Affymetrix HuGeneFL 7069 4990
Majumder, et al. [14] Broad Institute Affymetrix 430A 22691 11120
Prostate tumor datasets
Glinsky et al. [5] Oncomine Affymetrix U133A 22283 12768
Yu et al. [6] Oncomine Affymetrix U95Av2 12625 8762
Lapointe et al. [7] SMD spotted cDNA 43844 14310
Singh et al. [8] Broad Institute Affymetrix U95Av2 12625 8762
SMD–Stanford Microarray Database (http://genome-www5.stanford.edu)
GEO–Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
Broad Institute (http://www.broad.mit.edu/egi-bin/cancer/datasets.cgi)
Oncomine (www.oncomine.org)
doi:10.1371/journal.pone.0001816.t001
Table 2. Oncogenic pathway gene signatures surveyed in prostate cancer (PCA).
Oncogenic
pathway Study Model system
Number of unique
genes (up)
Number of unique
genes (down) FDR
cell cycle Whitfield, et al. [10] synchronized HeLa cell cultures 763 NA ,1%
androgen Deprimo, et al. [11] treatment of LNCaP prostate cells with R1881 259 23 54%
Chen, et al. [12] treatment of LNCaP prostate cells with R1881 559 761 1%
Myc Coller, et al. [13] conditional Myc-estrogen receptor fusion protein
in human primary fibroblast cells
252 238 9%
Bild, et al. [3] adenovirus infection of human primary mammary
epithelial cells (HMECs)
993 1369 1%
Ras Bild, et al. [3] ibid. 1777 2286 ,1%
E2F3 Bild, et al. [3] ibid. 2029 1867 ,1%
beta-catenin Bild, et al. [3] ibid. 976 1884 1%
Src Bild, et al. [3] ibid. 1566 1995 ,1%
erbB-2 Creighton, et al. [4] stable transfection of MCF-7 breast cancer cells 1315 1364 7%
MEK Creighton, et al. [4] ibid. 1238 1182 7%
EGFR Creighton, et al. [4] ibid. 734 940 11%
Raf Creighton, et al. [4] ibid. 618 988 11%
MAPK Creighton, et al. [4] ibid. 124 271 ,1%
cyclin D1 Lamb, et al. [2] adenovirus infection of MCF-7 breast cancer cells 206 109 22%
Akt Majumder, et al. [14] transgenic mouse prostate over-expressing human AKT1 770 775 1%
doi:10.1371/journal.pone.0001816.t002
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correlates of the oncogene were tested for enrichment of each of
the 16 oncogenic pathway signature gene sets of Table 2. As each
pathway signature had a set of genes up-regulated and another set
down-regulated in response to pathway activation, the ‘‘up’’ genes
were evaluated for enrichment separately from the ‘‘down’’ genes.
The test of enrichment used here was the rigorous, rank-based
‘‘Q1-Q2’’ statistic of Tian et al. [16] (schematic in Figure 2A),
which demonstrated significance of enrichment over what may be
expected using a randomly-generated set of pathway signature
genes (the ‘‘Q1’’ hypothesis) or using a random ordering of
reference oncogene values in the human tumor dataset (the ‘‘Q2’’
hypothesis). Besides the seven oncogenes of interest, other genes,
such as genes encoding MAPK or beta-catenin, were represented
by pathway signatures, though many of these other genes are
typically mutated or hyper-activated in cancer, rather than over-
expressed.
Results of the enrichment analysis are shown in Figure 2B. A
major advantage in evaluating four independent prostate tumor
datasets is that one may identify consistent patterns appearing in
Figure 1. Gene expression patterns indicative of oncogenic pathway deregulation. RNA profiling datasets were collected from various
published studies (described in Table 2) in which a particular pathway was activated in an experimental model. Expression patterns are represented
as a color map. Each row represents a gene; each column represents a sample. The level of expression of each gene in each sample is represented
using a yellow–blue color scale (yellow: high expression). Pathways represented are the following: (A) Myc, c-Src, beta-catenin, E2F3, and H-Ras, from
the study by Bild et al. [3]; (B) erbB-2 (HER2), EGFR, MEK, Raf, and MAPK from Creighton et al. [4]; (C) the cell cycle from Whitfield et al. [10]; (D)
androgen receptor (AR) signaling, from Deprimo et al. [11]; (E) AR signaling, from Chen et al. [12]; (F) Myc, from Coller et al. [13]; (G) cyclin D1, from
Lamb et al. [2]; (H) Akt, from Majumder et al. [14]. (I) Graphical representation of the significance of gene overlap (by one-sided Fisher’s exact test,
using as the reference population the entire set of 14130 genes represented among any of the array platforms) between the various pathway
signatures (focusing here on the sets of genes up-regulated in each signature).
doi:10.1371/journal.pone.0001816.g001
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three of the four datasets examined (though none were found in all
four). The major finding of the enrichment analysis was that genes
up-regulated experimentally by Myc, c-Src, HER2 (erbB-2), Akt,
or androgen were consistently co-expressed in human PCA with
Myc, c-Src, HER2, Akt, or PSA, respectively. Associations of the
Figure 2. Patterns of enrichment involving selected oncogenes (KLK3 i.e. PSA, MYC, SRC, ERBB2, EGFR, CCND1 i.e. cyclin D1, and AKT1)
and their corresponding pathway signature genes. (A) Schematic overview of Q1-Q2 enrichment analysis. Enrichment is defined as a
significant number of genes in the experimental set being located at or near the top of a population of genes rank-ordered by a given metric applied
to the human tumor dataset. (B) Results of enrichment analysis in four different gene expression profile datasets of human prostate tumors [5–8].
Patterns of consensus among the various datasets (i.e. patterns observed in at least 2 or 3 datasets) are also represented. For each oncogene-to-
pathway association, a red square indicates that genes in the pathway were enriched within the top genes most correlated with the oncogene. Anti-
enrichment (blue square) indicates that genes in the pathway overlapped with the genes most anti-correlated with the oncogene. Associations
between a given gene and its corresponding oncogenic pathway signature are highlighted with black outline.
doi:10.1371/journal.pone.0001816.g002
Pathways in Prostate Cancer
PLoS ONE | www.plosone.org 5 March 2008 | Volume 3 | Issue 3 | e1816cyclin D1 and EGFR pathway signatures with expression of
CCND1 and EGFR, respectively, were also observed in two of the
four tumor datasets. Many of the gene sets from different
oncogenic signature pathways shared significant overlap
(Figure 1I), yet, interestingly, each pathway set associated uniquely
with its corresponding oncogene; for example, the EGFR and
erbB-2 signatures had many genes in common (Figure 1B), yet the
EGFR signature genes did not associate with mRNA patterns of
erbB-2 in the human data, and vice versa (Figure 2B). Another
notable finding is that genes down-regulated in a given oncogenic
signature did not show anticipated patterns of anti-enrichment.
The Q1Q2 enrichment analysis of Figure 2B was a ranked-
based approach, where genes that were even weakly correlated
with the reference gene of interest could partially contribute to a
significant association (see ref [16] for details). Therefore, an
alternative enrichment method, the classical one-sided Fisher’s
exact test, was also considered. For each of the androgen, Myc,
Src, HER2, EGFR, cyclin D1, and Akt pathways, the top genes
overlapping between the oncogenic signature and the correlates of
the corresponding oncogene or biomarker in the human tumors
were tabulated. The numerical results of the tabulation are given
in Table 3, and the lists of genes overlapping between the
experimental and human datasets for each pathway signature are
given in Supplementary Data File S3. For Table 3 and
Supplementary Data File S3, positive correlation between a gene
and the given oncogene within the human tumors was defined as
showing statistical significance (p,0.05, Pearson’s correlation, two-
sided) in at least three out of the four prostate profile datasets.
Genes listed in Supplementary Data File S3 were therefore both in
the given pathway signature (as defined in Table 2) and
individually correlated with the corresponding oncogene or
biomarker in the human tumors.
Except for the EGFR signature, there was non-random overlap
between the set of genes in the experimentally-defined signature
and the set of genes correlated in the human tumors with the
reference oncogene or biomarker corresponding to the signature.
For example, of the 559 genes in the Chen androgen signature
(448 of which were represented in at least three prostate tumor
datasets), 29 were correlated (p,0.05) with KLK3 in at least three
out of the four prostate tumor datasets; by chance, nine were
expected, and so the amount of actual overlap was quite significant
(p=1.2E-08). The overlap was not significant for the EGFR
signature and was marginally significant (p=0.02) for the cyclin
D1 signature. The results of the Fisher’s exact enrichment analysis
(Table 3) appear consistent with the results of the Q1Q2
enrichment anlysis (Figure 2B), where the EGFR and CCND1
analyses were significant in only two of the four datasets; relatively
few genes (28) were individually correlated with EGFR mRNA in
at least three human tumor datasets, and genes that were
correlated in only two datasets would not have been included in
the Fisher’s exact analysis.
Discussion
In this study, several gene signatures of oncogenic pathways
defined experimentally were found to be coordinately expressed
with the single oncogene or biomarker corresponding to the
pathway in human prostate tumors. These results demonstrate
these signatures to be relevant to the study of human prostate
cancer. These findings apply mainly for the sets of genes up-
regulated in the signatures, as the down-regulated genes by and
large did not show expected correlation patterns (Figure 2B). The
gene-to-signature correlations of interest were observed in three of
the four prostate tumor profiles datasets, but none were found in
all four. The fact that no consistent patterns were found in all four
datasets is curious but could be explained by a number of reasons,
which could range from the technical (e.g. a ‘‘bad’’ gene probe or
chip artifact in one dataset) to the biological (e.g. different patient
cohorts being represented in different datasets). It should be
emphasized that any association made between a gene and its
corresponding signature for any one dataset was quite robust, the
significance values testing against 1000 randomly-generated gene
signature and 1000 permutations of the reference oncogene values
(see Methods). This study does underscore the value of the meta-
analysis approach, as patterns that may be missed in one profile
dataset could be repeatedly found in other datasets.
In general, experimental data might be expected to show
changes in gene expression that are merely artifacts of the model
system, while human tumor data alone can show patterns of
correlation but do not readily demonstrate cause-and-effect in the
way experimental models can. For a given pathway, the
intersection of the set of genes up-regulated by experimental
activation of the pathway with the set of genes showing anticipated
patterns of expression in human tumor tissue specimens would be
a set of genes of potential interest to researchers. For the Myc, c-
Src, HER2, EGFR, cyclin D1, Akt, and androgen pathways, this
study provides the set of genes relevant to each pathway both
Table 3. Number of genes overlapping between oncogenic signatures and human tumor correlates.
Oncogenic signature Signature genes* Prostate tumor genes** Expected overlap Actual overlap# P-value##
androgen_up_Chen 428 176 9 29 1.2E-08
Myc_up_Bild 475 150 8 33 7.9E-12
Src_up_Bild 767 116 11 23 0.0003
erbB-2_up_Creighton 1011 307 37 91 1.3E-17
EGFR_up_Creighton 560 28 2 1 0.85
cyclin_D1_up_Lamb 203 77 3 8 0.02
Akt_up_Majumder 512 262 20 47 3.6E-08
*Number of signature genes represented in at least three out of four prostate profile datasets.
**Number of genes positively correlated with corresponding oncogene/biomarker (see Figure 2A) in human prostate tumors (Criterion: p,0.05 in at least three out of
four profile datasets).
#Lists of overlapping genes included in Supplementary Data File S3.
##By one-sided Fisher’s exact test, using, as the reference population, the set of unique genes common to both the oncogene signature array platform and any three of
the prostate tumor array platforms (Chen, Creighton: 8500; Bild: 8402; Lamb: 4731; Majumder: 6560).
doi:10.1371/journal.pone.0001816.t003
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Data File S3). Molecular biologists who study any one of these
pathways may select candidate gene targets of these pathways
uncovered by this study and validate the expression patterns both
in experimental models (models using prostate cells in particular)
and in human prostate tumor specimens.
It is understood that a particular pathway may be deregulated
through a number of different genes [1], and so a measure of the
‘‘end point’’ of a signaling pathway at the transcription level may
prove to be a better indicator of pathway deregulation over any
single gene. The intersection of human and experimental profile
data provides sets of genes that could possibly be used in a clinical
diagnostic assay to infer which pathways are deregulated in patient
tumors. RT-PCR assays using RNA from paraffin-embedded
tissues have been developed [17], and so it would be technically
feasible to develop an RT-PCR-based, multi-gene assay for the
status of various pathways in a given tumor, using genes selected
from the results of this study.
The analysis presented here implicates over-expression of Myc,
Akt, c-Src, or erbB-2/HER2 with activation of their associated
pathways in at least a subset of prostate tumors. The roles of Myc
and Akt in prostate cancer initiation and progression have received
much study [18,19,14]. The c-Src oncogene has apparently not
received much attention in prostate cancer and is better known in
other cancers such as colon [20]. However, a truncated version of
the c-Kit prostate was recently found in primary prostate tumors,
which was correlated with activation of the Src pathway [21]. The
role of erbB-2 is prostate cancer has been controversial, and there
have been conflicting results over whether the gene is amplified or
over-expressed [19]. This present study indicates that there is a
sub-population of prostate cancer patients that express erbB-2 and
have its pathway activated; such patients could possibly benefit
from current anti-erbB2 therapies, such as Herceptin, currently in
use in breast cancer.
Other recent molecular profiling studies (in addition to those
referenced above) have demonstrated that gene expression
patterns derived from experimental models are also observable
in human tumors. For instance, transgenic mice over-expressing
Myc shared many of the expression patterns observed in human
prostate tumors having high MYC expression [22]; a mouse model
of Kras2-mediated lung cancer shared expression patterns with
human lung tumors harboring k-ras mutation [23]; and an SV40
T/t-antigen cancer gene signature activated in transgenic mouse
tumors with aberrant p53, Rb, or BRCA1 expression was
associated with poor prognosis in human breast, prostate, and
lung carcinomas [24]. In this context, the present study represents
a validation of the idea that gene expression patterns derived
experimentally can be relevant to the study of human cancer at the
transcriptomic level.
Materials and Methods
Gene expression profile datasets
The gene expression profile datasets described here were
publicly available [2–8,10–14] (Table 1). Gene expression values
were log-transformed. For the Chen androgen dataset [12],
expression values within the AR+ group of samples were
transformed to standard deviations from the mean; values within
the vector group of samples were separately transformed.
Treatment of the Coller et al. dataset [13] is described in ref
[15]. Human prostate tumor datasets were transformed to
standard deviations from the median. For the Lapointe et al.
cDNA microarray dataset [7], gene probes with missing values in
at least half of the tumor specimens were removed from
consideration. From the 66 PCA profiles described in the study
by Yu et al. [6], 60 were available for this study (collection for this
dataset was facilitated by A.M. Chinnaiyan and the Oncomine
team); the ‘‘adjacent tissue’’ (AT) profiles from the Yu study were
not considered here. Expression values were visualized as heat
maps using the Cluster [25] and Java TreeView software [26].
Definition of oncogenic pathway signatures
Two-sample t-tests determined significant differences in gene
expression between groups of samples. Criteria for selection of
genes in each oncogenic pathway signature was as follows: (1) Myc
signature from Bild dataset, p,0.001, comparing the Myc group
with GFP control; Bild Ras signature, p,0.00001; Bild E2F3
signature, p,0.001; Bild beta-catenin signature, p,0.001; Bild Src
signature, p,0.0001; erbB-2 (HER2) signature from Creighton
dataset, p,0.01, comparing HER2 group with MCF7/lt-E2
control; Creighton EGFR signature, p,0.01; Creighton MEK
signature, p,0.01; Creighton Raf signature, p,0.01; Creighton
MAPK signature, described in ref [4]; Whitfield cell cycle
signature, described in ref [10]; androgen receptor (AR) signaling
from Deprimo dataset, p,0.01, comparing R1881-treated LNCaP
samples with EtOH controls, and a minimum average red/green
ratio of 1.8 in R1881 samples; AR signaling from Chen dataset,
p,0.001 for Pearson’s correlation with log of R1881 concentra-
tion; Coller Myc signature, described in ref [15]; Lamb cyclin D1
signature, p,0.01 for Pearson’s correlation with CCND1 mRNA
expression across all samples; Majumder Akt signature, p,0.001,
comparing AKT-Tg mouse prostate with wild-type (placebo-
treated groups). False Discovery Rate (FDR) was computed for
each oncogenic signature, using the method of [27]; the number of
probes on the array was multiplied by the nominal p-value and
divided by the number of probes in the oncogenic signature (FDR
values listed in Table 2).
Enrichment analyses
In order to determine whether a specified group of experimen-
tally-derived genes (e.g. genes induced in the Myc signature) had a
coordinated association with a molecular phenotype of interest in
human tumors (e.g. prostate tumors with high MYC expression
relative to the other tumors), Q1-Q2 analysis was carried out
essentially as described in [16]. Briefly, the common population of
genes represented in the given human tumor profile dataset were
ranked based on Pearson’s correlation with the oncogene of
interest (using only the primary PCA profiles and not profiles from
metastatic or benign tissues). For genes in the experimental set of
interest, the t-scores for the correlation coefficients in the ranked
list were summed up; the significance of this sum was determined
both by 1000 randomly selected gene sets (the Q1 hypothesis) and
1000 random permutations of the values for the reference gene
(i.e. the oncogene used to rank the other genes) in the tumor
dataset (the Q2 hypothesis). The sum of t-scores from the actual
datasets were expressed as standard deviations from the mean of
either the Q1 permutation results or the Q2 permutation results,
with two-sided significance p-values determined assuming normal
distributions of the permutation results. The higher of the Q1 and
Q2 p-values determined enrichment (with both Q1 and Q2
required to move in the same direction).
The Entrez Gene identifier was used in mapping genes across
the array datasets. For the prostate tumor datasets, where a gene
was represented multiple times on a given platform, the ‘‘best’’
probe for the gene was selected in a manner not biased towards
the direction of relative expression changes (the probe with the
largest average signal intensity for the prostate tumor Affymetrix
datasets, the probe with the least missing values across samples for
Pathways in Prostate Cancer
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signature gene sets, where a gene was represented by multiple
array probes, the gene was represented at most once in a given set
(it was possible within a signature for a given gene to be
represented in both the ‘‘up’’ lists and the ‘‘down’’ lists by different
probes, though this was the case for only a handful of genes).
Where the probe selected to represent the reference oncogene or
biomarker for ranking the entire gene population failed to show a
significant association with the corresponding oncogenic signature,
alternative probes representing the oncogene were tried.
Supporting Information
Supplementary Data File S1 Lists of unique named genes in
each of the oncogenic pathway signatures of Table 2
Found at: doi:10.1371/journal.pone.0001816.s001 (2.53 MB
XLS)
Supplementary Data File S2 Lists of the corresponding genes
overlapping among the various oncogenic signatures.
Found at: doi:10.1371/journal.pone.0001816.s002 (3.42 MB
XLS)
Supplementary Data File S3 For each of the androgen, Myc,
Src, HER2, EGFR, cyclin D1, and Akt pathways, lists of genes
overlapping between the oncogenic signature and correlates of the
corresponding oncogene or biomarker in human prostate tumors.
Found at: doi:10.1371/journal.pone.0001816.s003 (1.41 MB
XLS)
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